A practical pharmacy review starts with what the patient already takes. Comparing supplement labels with dietary intake helps identify gaps without automatically adding another product. Patients at elevated fracture risk need assessment for pharmacologic protection; supplements alone do not replace indicated treatment.2
Match the Drug to the Treatment Goal
Fracture prevention and recurrence reduction are separate reasons to prescribe bone-modifying therapy. For osteoporosis or elevated fracture risk in nonmetastatic cancer survivors, ASCO identifies bisphosphonates or denosumab (Prolia, Xgeva; Amgen) at osteoporosis-indicated doses as preferred options when medication is needed.2
The randomized ABCSG-18 trial (NCT00556374) provides direct fracture evidence for denosumab. Among 3420 postmenopausal patients receiving aromatase inhibitors for hormone receptor–positive early breast cancer, denosumab 60 mg subcutaneously every 6 months reduced the hazard of a first clinical fracture compared with placebo (HR, 0.50; 95% CI, 0.39–0.65; P < .0001). Investigators reported 92 fractures with denosumab versus 176 with placebo.3
For recurrence prevention, the ASCO–Ontario Health guideline recommends discussing adjuvant bisphosphonates with postmenopausal patients, including those with therapy-induced menopause, who are candidates for adjuvant systemic therapy. Expected benefit depends on recurrence risk and must be weighed against adverse effects and patient preferences. The guideline does not recommend adjuvant denosumab to prevent recurrence because findings have been inconsistent.4
Documenting the indication helps pharmacists verify that the regimen matches its intended purpose.
Plan for Safety and Continuity
Before denosumab begins, preexisting hypocalcemia must be corrected. Its prescribing information includes a boxed warning for severe hypocalcemia in advanced chronic kidney disease, particularly when chronic kidney disease–mineral and bone disorder is present. These patients require specialist supervision and close calcium monitoring.5
Dental assessment also matters. Denosumab labeling recommends an oral examination before treatment and preventive dentistry for patients with osteonecrosis-of-the-jaw risk factors. Pharmacists can reinforce oral hygiene and encourage communication about planned invasive dental procedures.5
Discontinuation requires a plan: multiple vertebral fractures have occurred after denosumab is stopped, and labeling directs transition to another antiresorptive agent. Tracking injection dates and escalating access problems can help prevent an unintended interruption.5
At each endocrine therapy refill, pharmacists can reconnect the patient with the bone health plan: confirm the next assessment, address medication concerns, and identify who will manage follow-up. That continuity makes fracture prevention part of everyday breast cancer care.
